Intergroupe Francophone De Cancerologie Thoracique

This study tested the drug durvalumab in 50 people with advanced stage IV non-small cell lung cancer who had poor overall health (ECOG 2-3) and had not received prior treatment. The goal was to see if the drug could control the cancer and be safe for these patients, who are often…

This study looked at 265 people with advanced non-small cell lung cancer whose tumors have a protein called PD-L1. All patients received a combination of two immunotherapy drugs (nivolumab and ipilimumab) for 6 months. Then, half stopped treatment and were watched closely, while …